Mouse hepatomas with Ha-ras and B-raf mutations differ in mitogen-activated protein kinase signaling and response to constitutive androstane receptor activation

Data Supplement

• Supplemental Data -

  Supplemental Figure 1 - Schematic representation (not to scale) of the treatment protocol
  

  Supplemental Figure 2 - Western Blot verification of differential expression of the CAR targets in normal liver (NL) and in mouse liver tumors with activating mutations in either Ha-ras (Ras) or B-raf (Raf)
  

  Supplemental Figure 3 - CAR mRNA levels in normal liver (NL) and mouse liver tumors with activating mutations in either Ha-ras (Ras) or B-raf (Raf)
  

  Supplementary Table 1 - Antibodies used for RPPA assay